Kyntra Bio, Inc. (KYNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has a cash flow conversion efficiency ratio of -4.096x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.33 Million) by net assets ($4.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KYNB net asset quality index to measure how much of total assets are equity-financed.
Kyntra Bio, Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check KYNB cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Kyntra Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyntra Bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iconic Worldwide Bhd
KLSE:9113
|
-0.018x |
|
Mega Perintis Tbk PT
JK:ZONE
|
-0.109x |
|
Signetics Corporation
KQ:033170
|
-0.033x |
|
UCAL Limited
NSE:UCAL
|
N/A |
|
Highest Performances Holdings Inc.
NASDAQ:HPH
|
-0.004x |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
-0.364x |
|
Hamilton Global Opportunities PLC
PA:ALHGO
|
-0.012x |
|
NSC Groupe SA
PA:ALNSC
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Kyntra Bio, Inc. from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Kyntra Bio, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.47 Million | $-4.77 Million | -1.067x | -241.96% |
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more